Yesterday’s announcement that the EMA Management Board may have adopted a less obstructive policy to releasing clinical trial data comes hard on the heels of widespread coverage (see here, here, […]
Tom Jefferson and Peter Doshi are two of the guys who battled for four years to access clinical study reports on antivirals for influenza for their Cochrane review. Here they […]
How does a doctor obtain informed consent for H1N1 immunisation consistent with General Medical Council guidance? The Department of Health’s guidance does not provide sufficient information for this. This is […]
England’s chief medical officer Sir Liam Donaldson can sound gloomy and pessimistic but he sounded very upbeat in this week’s swine flu update, saying: “We may have got a lucky […]
On 31 May 2021, a group of researchers and NGOs (see list of signatories in the acknowledgement section below) submitted an open letter to the Heads of Medicines Agencies, a […]
In March 2017 Health Canada released a discussion paper promising a new era in transparency. The agency committed itself to proactively releasing clinical trial data submitted by drug companies, similar […]
Health Canada has been talking about improving the transparency of information around pharmaceutical drugs for years. And for years the drug regulator has failed to back up that talk with […]
The European Medicines Agency (EMA) has issued its long anticipated new policy (policy 0070) on prospective access to clinical trial data, and is now in consultations to figure out the […]
Pamplona 2015—The General Assembly of the International Society of Drug Bulletins (ISDB) At the end of June, the city of Pamplona was getting ready to celebrate the fiestas in honour […]
NEJM 5 Feb 2015 Vol 372 519 Refractory angina seems to be common in cardiac clinics but not in primary care. When all the drugs have failed, and revascularization is […]
